New Lupus Drug Gets Approval — First of Its Kind in Years
The FDA approved Gazyva (obinutuzumab) on October 20, 2025, for adult patients with active lupus nephritis — making it only the third drug ever greenlit...
Category Tools
Why Nerve Pain Is So Hard to Treat — And the New Approaches That Work
Nerve pain is so difficult to treat because it does not behave like ordinary pain. While a broken bone or a pulled muscle sends a clear, proportional...
The Food Triggers Behind Migraines That Your Neurologist Wants You to Track
The foods most likely to trigger your migraines are ones you probably consume every day: chocolate, cheese, coffee, wine, and tea.
The Migraine Medication That Can Cause Permanent Rebound Headaches
The migraine medications most likely to cause permanent-feeling rebound headaches are combination analgesics containing opioids or barbiturates — drugs...
The Sedating Antipsychotic Prescribed to Nursing Home Patients — And Why It’s Controversial
The sedating antipsychotic at the center of this controversy is quetiapine, sold under the brand name Seroquel.
Why ADHD Medication Works for Some Adults but Not Others
ADHD medication works for some adults and not others primarily because of individual differences in brain chemistry — specifically, the ratio of dopamine...
The ADHD Medication That’s Causing Dangerous Heart Problems in Adults
It is not one single ADHD medication causing heart problems in adults — it is nearly all of them, including several that most patients and even some...
Adderall Shortage 2025: Why It’s Still Happening and When It’ll End
The Adderall shortage that began making headlines in 2022 is still not over. As of early 2026, both immediate-release and extended-release formulations of...
The Heart Medication That Works Better When You Take It at Night
Blood pressure medications, particularly ACE inhibitors and ARBs, may offer modestly better blood pressure control when taken at bedtime rather than in...
New Crohn’s Drug Gets Fast-Track Approval — Here’s What It Does
A drug called ontunisertib, developed by Agomab Therapeutics, has received FDA fast-track designation for fibrostenosing Crohn's disease — making it the...